GHRH receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-26 and is reviewed periodically as new material appears.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
=== Gait === The hunched position that often results from complete spinal fusion can have an effect on a person's gait. Increased spinal kyphosis will lead to a forward and downward shift in center of mass (COM). This shift in COM has been shown to be compensated by increased knee flexion and ankle dorsiflexion. The gait of someone with ankylosing spondylitis often has a cautious pattern because they have decreased ability to absorb shock, and they cannot see the horizon.
== Side effects == Deltamethrin belongs to a group of pesticides called synthetic pyrethroids. This pesticide is toxic to aquatic life, particularly fish, and therefore must be used with extreme caution around water.
October 8 – The US begins direct negotiations with the military junta while continuing sanctions against its leader, Min Aung Hlaing, for human rights violations, notably the Rohingya genocide. The Pentagon instructs the US Central Command to get ready in case direct military operations against Iran were to resume. U.S. and Israeli officials suggests that joint strikes against Iranian nuclear, energy, and infrastructure sites might take place prior to either the November US midterm elections or the late October Israeli general election, even though Trump had not made a final decision or established a timeline. Internal assessments and energy analysts cautions that renewed hostilities would fail to lower immediate gasoline prices and could instead cause a sharp spike in global oil prices, despite the administration's goal of a military breakthrough to eventually lower domestic fuel costs. Further sanctions are put by the US on Iran's shadow fleet.
Absolute bioavailability compares the bioavailability of the active drug in systemic circulation following non-intravenous administration (i.e., after oral, buccal, ocular, nasal, rectal, transdermal, subcutaneous, or sublingual administration), with the bioavailability of the same drug following intravenous administration. It is the fraction of exposure to a drug (AUC) through non-intravenous administration compared with the corresponding intravenous administration of the same drug. The comparison must be dose normalized (e.g., account for different doses or varying weights of the subjects); consequently, the amount absorbed is corrected by dividing the corresponding dose administered. In pharmacology, in order to determine absolute bioavailability of a drug, a pharmacokinetic study must be done to obtain a plasma drug concentration vs time plot for the drug after both intravenous (iv) and extravascular (non-intravenous, i.e., oral) administration. The absolute bioavailability is the dose-corrected area under curve (AUC) non-intravenous divided by AUC intravenous. The formula for calculating the absolute bioavailability, F, of a drug administered orally (po) is given below (where D is dose administered).
Natural calcium is a mixture of five stable isotopes—40Ca, 42Ca, 43Ca, 44Ca, and 46Ca—and 48Ca, whose half-life of 4.3 × 1019 years is so long that it can be considered stable for all practical purposes. Calcium is the first (lightest) element to have six naturally occurring isotopes. By far the most common isotope is 40Ca, which makes up 96.941% of natural calcium. It is produced in the silicon-burning process from fusion of alpha particles and is the heaviest stable nuclide with equal proton and neutron numbers; its occurrence is also supplemented slowly by the decay of primordial 40K. Adding another alpha particle leads to unstable 44Ti, which decays via two successive electron captures to stable 44Ca; this makes up 2.806% of natural calcium and is the second-most common isotope. The other four natural isotopes, 42, 43, 46, 48Ca, are significantly rarer, each comprising less than 1% of natural calcium. The four lighter isotopes are mainly products of oxygen-burning and silicon-burning, leaving the two heavier ones to be produced via neutron capture. 46Ca is mostly produced in a "hot" s-process, as its formation requires a rather high neutron flux to allow short-lived 45Ca to capture a neutron. 48Ca is produced by electron capture in the r-process in type Ia supernovae, where high neutron excess and low enough entropy ensures its survival. 46Ca and 48Ca are the first "classically stable" nuclides with a 6-neutron or 8-neutron excess respectively.
Sources: en.wikipedia.org
== External links == Clinical trial number NCT02715258 for "Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes" at ClinicalTrials.gov Clinical trial number NCT03259789 for "Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects" at ClinicalTrials.gov Clinical trial number NCT02769481 for "Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects" at ClinicalTrials.gov Clinical trial number NCT03115112 for "Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects" at ClinicalTrials.gov Clinical trial number NCT02836873 for "Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment" at ClinicalTrials.gov Clinical trial number NCT02558296 for "Bexagliflozin Efficacy and Safety Trial (BEST)" at ClinicalTrials.gov
Bryza said that by the night of 7 August, he had called on the Georgian officials not to open fire on the invading Russians. Evgeny Gontmakher, member of the board of the Institute of Contemporary Development, said that he was told by employees of the Russian government that the major resolutions during the war were not made without Putin. Brigadier general Kārlis Krēsliņš said in an interview that Russian assertion that the war began on the night of 7 to 8 August was not true because six Georgian policemen were targeted by mine on 1 August and a Georgian village was bombarded on 2 August from the Ossetian-inhabited territory controlled by the Russian peacekeepers. Krēsliņš said that the Georgian servicemen noticed in 2008 that Ossetians continued to shoot whether did the Georgian troops return fire or not. Krēsliņš commented on the Russian readiness, "The [Russian] military was expecting only an order, and politicians organized the reason for such an order to be given." Krēsliņš said that Georgia noticed how the Russian troops were amassing on the border, but Georgia did not believe that Russia would attack, although Georgia was expecting that a Russian attack would probably begin in Abkhazia. He stated that Georgia was not prepared for the Russian invasion. Krēsliņš opined that Georgia could successfully defend against the Russian invasion due to its mountains, however, according to his information, Georgia ruled out this because Russia threatened to destroy the country's capital from the air. On 18 September 2008, the U.S.
Validation - The first definition indicates confirmation (through the provision of strong, sound, objective evidence) that requirements for a specific intended use or application have been fulfilled. However, within the family of definitions, it is frequently used in a manner synonymous with verification. Verification - often used to indicate a persona or identity has been verified against a database, such as a PIN-protected identify certificate matches a controlled access list.
The α-Ketoacid-Hydroxylamine (KAHA) Amide-Forming Ligation is a chemical reaction that is used to join two unprotected fragments in peptide synthesis. It is an alternative to the Native Chemical Ligation (NCL). KAHA Ligation was developed by Jeffrey W. Bode group at ETH Zürich (previously University of Pennsylvania).
=== Psychosocial === Peyronie's disease can also have psychological effects. While most men will continue to be able to have sexual relations, they are likely to experience some degree of erectile dysfunction. It is not uncommon to exhibit depression or withdrawal from their sexual partners. In one study, 81% of men diagnosed with Peyronie's disease reported emotional difficulties. 48% reported clinically meaningful depression. Of those, 26% experienced moderate depression, while 21% experienced severe depression. 54% reported relationship problems due to Peyronie's disease. Peyronie's disease can cause patients to feel socially isolated and stigmatized. Physicians may be unaware of the psychological effects suffered by patients and their partners. Many men with Peyronie's disease avoid intimacy and isolate themselves as they cope with anger, depression, fear of rejection, and decreased self‐worth.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.